Technical Analysis for BLUE - bluebird bio, Inc.

Grade Last Price % Change Price Change
grade C 178.95 -0.33% -0.60
BLUE closed down 0.33 percent on Thursday, July 19, 2018, on 56 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Aug 1

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Flat Up
See historical BLUE trend table...

Date Alert Name Type % Chg
Jul 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jul 19 Narrow Range Bar Range Contraction 0.00%
Jul 19 NR7 Range Contraction 0.00%
Jul 19 NR7-2 Range Contraction 0.00%
Jul 19 Multiple of Ten Bearish Other 0.00%
Jul 19 Inside Day Range Contraction 0.00%
Jul 19 Overbought Stochastic Strength 0.00%
Jul 18 50 DMA Support Bullish -0.33%
Jul 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.33%
Jul 18 NR7 Range Contraction -0.33%

Older signals for BLUE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on the development, manufacture, and marketing of therapies to treat various human diseases. Its product candidates include Lenti-D to treat patients with childhood cerebral adrenoleukodystrophy (ALD), a hereditary neurological disorder, as well as for the treatment of adult cerebral ALD; and CAR T cells products for treating oncology diseases. The company's product candidates also comprise LentiGlobin vector for the treatment of ß-thalassemia, a hereditary blood disorder; and sickle cell diseases. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Is BLUE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 236.17
52 Week Low 85.65
Average Volume 892,559
200-Day Moving Average 176.1936
50-Day Moving Average 178.131
20-Day Moving Average 169.7225
10-Day Moving Average 177.69
Average True Range 7.2502
ADX 16.9
+DI 27.6604
-DI 20.0237
Chandelier Exit (Long, 3 ATRs ) 167.5594
Chandelier Exit (Short, 3 ATRs ) 170.5106
Upper Bollinger Band 191.1869
Lower Bollinger Band 148.2581
Percent B (%b) 0.71
BandWidth 25.293523
MACD Line 1.0676
MACD Signal Line -0.8934
MACD Histogram 1.9609
Fundamentals Value
Market Cap 8.16 Billion
Num Shares 45.6 Million
EPS -7.33
Price-to-Earnings (P/E) Ratio -24.41
Price-to-Sales 233.66
Price-to-Book 5.18
PEG Ratio 0.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 183.15
Resistance 3 (R3) 183.43 182.32 182.45
Resistance 2 (R2) 182.32 181.25 182.18 182.22
Resistance 1 (R1) 180.63 180.59 180.08 180.35 181.98
Pivot Point 179.52 179.52 179.24 179.38 179.52
Support 1 (S1) 177.83 178.45 177.28 177.55 175.92
Support 2 (S2) 176.72 177.79 176.58 175.68
Support 3 (S3) 175.03 176.72 175.45
Support 4 (S4) 174.75